The Thai Journal of Veterinary Medicine


Blood pressure, renal function, urinary protein excretion and red blood cell count were measured in 29 dogswith chronic kidney disease which received hormone recombinant human Erythropoietin (rHuEPO). The experimentwas divided into 2 parts. Parts 1 comprised 3 groups of dogs. Group 1 dogs were studied prior to erythropoietin(EPO) injection (pre-EPO). Group 2 dogs received EPO 100 U/kg 2-3 times a week. Group 3 dogs received both EPOand angiotensin converting enzyme inhibitor which was enalapril 5 mg/kg/daily. The duration of medication wasbetween 7 to 40 days. In part 2 of the experiment, all parameters were measured in the same dogs before and after thedogs received EPO alone or EPO with ACEI for 15 days. The results showed that dogs with CKD before EPO injection(group 1) had non regenerative anemia with elevated blood urea nitrogen and plasma creatinine concentrations. Theblood pressure was within normal limit while the urinary excretion of protein, Na and K were enhanced. Group 2and group 3 had no significant differences in all of these parameters except a significant increase in RBC production.Group 2 tended to have higher increase in RBC production more than group 3. In part 2 in which the study wasperformed in the same dogs, there were no changes in blood pressure and renal function. However, 15 days afterEPO or EPO with ACEI, the significant increases in packed cell volume were found in dogs receiving EPO alone(p<0.01) and with ACEI (p<0.05) and the degree of EPO activated RBC production was greater in dogs receiving EPOalone (p<0.05). It is concluded that giving EPO either alone or with ACEI had no effect on blood pressure, renalfunction and urinary protein excretion in dogs with CKD, suggesting no angiotensin II involvement. However, bycomparing with the same EPO intensity, dogs with CKD receiving ACEI required more EPO at the initial phase oftreatment in order to yield the same increase in PCV.

First Page


Last Page